PortfoliosLab logo
3SBio Inc (1530.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

KYG8875G1029

IPO Date

Feb 7, 2007

Highlights

Market Cap

HK$28.45B

PE Ratio

13.27

PEG Ratio

3.33

Year Range

HK$10.94 - HK$13.28

Target Price

HK$12.20

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period


1530.HK

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.64%

1M

8.97%

6M

-2.52%

1Y

11.90%

5Y*

15.34%

10Y*

10.70%

*Annualized

Monthly Returns

The table below presents the monthly returns of 1530.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-9.37%-9.37%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 91, 1530.HK is among the top 9% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of 1530.HK is 9191
Overall Rank
The Sharpe Ratio Rank of 1530.HK is 9393
Sharpe Ratio Rank
The Sortino Ratio Rank of 1530.HK is 9090
Sortino Ratio Rank
The Omega Ratio Rank of 1530.HK is 9292
Omega Ratio Rank
The Calmar Ratio Rank of 1530.HK is 8989
Calmar Ratio Rank
The Martin Ratio Rank of 1530.HK is 9292
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for 3SBio Inc (1530.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for 3SBio Inc. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Dividends

Dividend History


3SBio Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the 3SBio Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the 3SBio Inc was 9.37%, occurring on May 12, 2025. The portfolio has not yet recovered.

The current 3SBio Inc drawdown is 9.37%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-9.37%May 7, 20254May 12, 2025

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of 3SBio Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of 3SBio Inc, comparing actual results with analytics estimates. The company met analyst expectations for EPS in the past quarter.


0.000.050.100.150.200.250.300.35AprilJulyOctober2019AprilJulyOctober2020AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober
0.32
0.32
Actual
Estimate

Valuation

The Valuation section provides an overview of how 3SBio Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for 1530.HK, comparing it with other companies in the Biotechnology industry. Currently, 1530.HK has a P/E ratio of 13.3. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for 1530.HK compared to other companies in the Biotechnology industry. 1530.HK currently has a PEG ratio of 3.3. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for 1530.HK relative to other companies in the Biotechnology industry. Currently, 1530.HK has a P/S ratio of 2.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for 1530.HK in comparison with other companies in the Biotechnology industry. Currently, 1530.HK has a P/B value of 1.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items